A. Crow

A. Lazarus, A. Crow, 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Role of Fc&ggr; Receptors in the Pathogenesis and Treatment of Idiopathic Thrombocytopenic Purpura

A. Lazarus, A. Crow, 2003 .

IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity.

K. Siminovitch, J. Freedman, C. Helgason, 2003, Blood.

Understanding platelet function through signal transduction.

A. Lazarus, A. Crow, S. Song, 2003, Transfusion medicine reviews.

The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia.

X. Chen, A. Lazarus, A. Crow, 2011, Blood.

model of ITP: an alternative to IVIG Monoclonal IgG can ameliorate immune thrombocytopenia in a murine

J. Freedman, A. Lazarus, A. Crow, 2013 .

Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG.

J. Freedman, A. Lazarus, A. Crow, 2003, Blood.

A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?

J. Freedman, A. Lazarus, J. Semple, 2007, Blood.

Amelioration of Murine Passive Immune Thrombocytopenia by IVIg and a Therapeutic Monoclonal CD44 Antibody Does Not Require the Myd88 Signaling Pathway

A. Lazarus, A. Crow, Honghui Yu, 2013, PloS one.

Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo.

J. Freedman, F. P. Nestel, A. Lazarus, 2006, Blood.

Inhibition of a secondary human alloimmune response via the soluble active component of CD154 (CD40L) in severe combined immune‐deficient mice engrafted with human lymphocytes

J. Freedman, V. Blanchette, A. Lazarus, 1999, Transfusion.

Altered Thymic and Peripheral T-Lymphocyte Repertoire Preceding Onset of Diabetes in NOD Mice

T. Delovitch, D. Zipris, A. Crow, 1991, Diabetes.

Analysis of transmembrane signalling and T cell defects associated with idiopathic thrombocytopenic purpura (ITP)

A. Lazarus, A. Crow, T. Joy, 1998, Acta paediatrica (Oslo, Norway : 1992). Supplement.

Role of macrophage procoagulant activity in mouse hepatitis virus (MHV) infection: studies using T cell MHV-3 clones and monoclonal antibody 3D4.3.

S. Perlman, S. Chung, Chengjin Li, 1993, Advances in experimental medicine and biology.

New insight into the mechanism of action of IVIg: the role of dendritic cells

A. Lazarus, D. Brinc, A. Crow, 2009, Journal of thrombosis and haemostasis : JTH.

CD44 antibody–mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcγRIIb genetic disruption

A. Lazarus, A. Crow, A. Amash, 2015, Transfusion.

The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?

A. Lazarus, A. Crow, 2008, Transfusion medicine reviews.

Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?

J. Freedman, A. Lazarus, D. Brinc, 2005, The Journal of clinical investigation.

Intravenous immunoglobulin products: an update on their mechanisms of action

J. Freedman, A. Lazarus, A. Crow, 2008 .

Monoclonal antibody analysis of a unique macrophage procoagulant activity induced by murine hepatitis virus strain 3 infection.

S. Chung, J. Leibowitz, G. Levy, 1991, The Journal of biological chemistry.

Mechanistic properties of intravenous immunoglobulin in murine immune thrombocytopenia: support for FcγRIIB falls by the wayside.

A. Lazarus, A. Crow, 2016, Seminars in hematology.

A method for ameliorating autoimmune disease by passive transfer of IVIg-primed leukocytes

J. Freedman, A. Lazarus, D. Brinc, 2006 .

Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia

A. Lazarus, V. Siragam, A. Crow, 2006, Pediatric blood & cancer.

IgG‐mediated immunosuppression is not dependent on erythrocyte clearance or immunological evasion: implications for the mechanism of action of anti‐D in the prevention of haemolytic disease of the newborn?

J. Freedman, A. Lazarus, D. Brinc, 2007, British journal of haematology.

IVIg inhibits reticuloendothelial system function and ameliorates murine passive‐immune thrombocytopenia independent of anti‐idiotype reactivity

J. Freedman, A. Lazarus, J. Semple, 2001, British journal of haematology.

Monoclonal antibody‐mediated inhibition of the human HLA alloimmune response to platelet transfusion is antigen specific and independent of Fcγ receptor‐mediated immune suppression

J. Freedman, A. Lazarus, A. Crow, 2000, British journal of haematology.

Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg.

J. Freedman, A. Lazarus, V. Siragam, 2005, Blood.

Comparison of platelet immunity in patients with SLE and with ITP.

J. Freedman, A. Lazarus, A. Crow, 2000, Transfusion science.

Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?

A. Lazarus, M. P. Reilly, A. Crow, 2011, Blood.

Antigen-induced Fc receptor-dependent and -independent B cell desensitization. An elevation in [Ca2+]i is not sufficient and protein kinase C activation is not required for these pathways of surface IgM-mediated desensitization.

G. Mills, A. Lazarus, T. Delovitch, 1991, Journal of Immunology.

Inhibition of Immune Thrombocytopenic Purpura (ITP) by an Orally Bioavailable Inhibitor of Syk Kinase Activity.

J. Freedman, E. Masuda, A. Lazarus, 2005 .

New insight into the mechanism of action of IVIg: the role of dendritic cells

A. Lazarus, D. Brinc, A. Crow, 2009, Journal of thrombosis and haemostasis : JTH.